<p>This is a summary of the European public assessment report (EPAR) for Iasibon. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Iasibon.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p><strong>Concentrate for solution for infusion</strong></p> <p>Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.</p> <p>Treatment of tumour-induced hypercalcaemia with or without metastases.</p> <p><strong>Film-coated Tablets</strong></p> <p>Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.</p></div>
Therapeutic Area (MeSH)
ATC Code
M05BA06
ATC Item
N/A
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ibandronic acid | N/A | ibandronic acid |
EMA Name
Iasibon
Medicine Name
Iasibon
Aliases
N/ANo risk management plan link.
